Insys Therapeutics has agreed to pay a hefty $225 million to settle criminal and civil investigations into unlawful marketing practices – including kickbacks – to boost sales of an opioid p
Results from a new study of Pfizer and Lilly’s non-opioid pain drug tanezumab have shown that it can be effective in osteoarthritis in higher doses, but lower doses remain ineffective and the dr
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
